Analysis of LItigated Biologics Patents (Article III vs. IPR)
<|begin_of_text|><|start_header_id|>system<|end_header_id|> You are a research archivist expert in dataset metadata. Answer the question truthfully.  <|eot_id|><|start_header_id|>user<|end_header_id|> Here is the Description of a dataset. Description:'This set of files characterizes biologics patents litigated in district court since Congressional creation of a biosimilar pathway in 2010 and compares their characteristics to those of biologics patents litigated at the Patent Trial and Appeals Board since 2012' . Please return only a json list of at most 3 Keywords corresponding to the Description:.<|eot_id|><|start_header_id|>assistant<|end_header_id|> {"Answer" : ["biological products"]} <|eot_id|>
 Here is the Description of a dataset. Description:'This set of files characterizes biologics patents litigated in district court since Congressional creation of a biosimilar pathway in 2010 and compares their characteristics to those of biologics patents litigated at the Patent Trial and Appeals Board since 2012' . Please return only a json list of at most 3 Keywords corresponding to the Description:.
This set of files characterizes biologics patents litigated in district court since Congressional creation of a biosimilar pathway in 2010 and compares their characteristics to those of biologics patents litigated at the Patent Trial and Appeals Board since 2012
biological products